Aromatase inhibitors: a dose-response effect?
Smith
I E
IE
Section of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
D000616:Aminoglutethimide / Q000494:pharmacology / Q000627:therapeutic use; D000077384:Anastrozole; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism*; D017316:Fadrozole / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077289:Letrozole; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004967:Estrogens; D009570:Nitriles; D014230:Triazoles; D000616:Aminoglutethimide; D000077384:Anastrozole; D000077289:Letrozole; D017316:Fadrozole